Clinical trialNCT05001880RecruitingPhase 2Interventional

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

SponsorNational Cancer Institute (NCI)Enrollment66Peritoneal Malignant Mesothelioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Aaron S Mansfield
Alliance for Clinical Trials in Oncology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
Suspended
Alliance for Clinical Trials in Oncology
Chicago, Illinois, United States
Aaron S. Mansfield
Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Hedy L. Kindler →
Recruiting
Carle at the Riverfront
Danville, Illinois, United States
Suparna Mantha
Recruiting
Carle Physician Group-Effingham
Effingham, Illinois, United States
Suparna Mantha
Recruiting
Carle Physician Group-Mattoon/charleston
Mattoon, Illinois, United States
Suparna Mantha
Recruiting
Carle Cancer Center
Urbana, Illinois, United States
Suparna Mantha
Recruiting
the Carle Foundation Hospital
Urbana, Illinois, United States
Suparna Mantha
Recruiting
University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
Active, not recruiting
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, United States
Daniel Almquist
Recruiting
Mercy Hospital
Coon Rapids, Minnesota, United States
Yan Ji
Recruiting
Fairview Southdale Hospital
Edina, Minnesota, United States
Yan Ji
Recruiting
Unity Hospital
Fridley, Minnesota, United States
Active, not recruiting
Abbott-Northwestern Hospital
Minneapolis, Minnesota, United States
Yan Ji
Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Aaron S. Mansfield
Recruiting
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, United States
Yan Ji
Recruiting
Regions Hospital
Saint Paul, Minnesota, United States
Yan Ji
Recruiting
United Hospital
Saint Paul, Minnesota, United States
Yan Ji
Recruiting
Rice Memorial Hospital
Willmar, Minnesota, United States
Yan Ji
Recruiting
Sanford Cancer Center Worthington
Worthington, Minnesota, United States
Daniel Almquist
Recruiting
Sanford Bismarck Medical Center
Bismarck, North Dakota, United States
Daniel Almquist
Recruiting
Sanford Broadway Medical Center
Fargo, North Dakota, United States
Daniel Almquist
Recruiting
Sanford Roger Maris Cancer Center
Fargo, North Dakota, United States
Daniel Almquist
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
John L. Hays
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Hassan Hatoum
Recruiting
Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Liza C. Villaruz
Recruiting
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, United States
Daniel Almquist
Recruiting
Sanford Usd Medical Center - Sioux Falls
Sioux Falls, South Dakota, United States
Daniel Almquist
Recruiting
Ut Md Anderson - the Woodlands
Conroe, Texas, United States
Kanwal P. Raghav
Recruiting
Ut Md Anderson - West Houston
Houston, Texas, United States
Kanwal P. Raghav
Recruiting
Ut Md Anderson Cancer Center
Houston, Texas, United States
Kanwal P. Raghav
Recruiting
Ut Md Anderson - League City
League City, Texas, United States
Kanwal P. Raghav
Recruiting
Ut Md Anderson - Sugar Land
Sugar Land, Texas, United States
Kanwal P. Raghav
Recruiting
Thedacare Regional Cancer Center
Appleton, Wisconsin, United States
Matthias Weiss
Recruiting
Marshfield Medical Center-Ec Cancer Center
Eau Claire, Wisconsin, United States
Michael Husak
Recruiting
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, United States
Michael Husak
Recruiting
Marshfield Medical Center - Minocqua
Minocqua, Wisconsin, United States
Michael Husak
Recruiting
Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin, United States
Michael Husak
Recruiting
Marshfield Medical Center-River Region at Stevens Point
Stevens Point, Wisconsin, United States
Michael Husak
Recruiting
Marshfield Medical Center - Weston
Weston, Wisconsin, United States
Michael Husak
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →Bevacizumab →Carboplatin →Hyperthermic Intraperitoneal ChemotherapyPemetrexed →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 Mar 2022
Primary completion: 1 Aug 2027
Completion: 1 Aug 2027
Last update posted: 13 Aug 2026
Registered enrollment: 66
Registry id: NCT05001880

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.